O	0	8	Efficacy
O	9	11	of
B-intervention	12	23	neoadjuvant
I-intervention	24	33	endocrine
I-intervention	34	41	therapy
O	42	50	compared
O	51	55	with
B-control	56	67	neoadjuvant
I-control	68	80	chemotherapy
O	81	83	in
O	84	87	pre
O	87	88	-
O	88	98	menopausal
O	99	107	patients
O	108	112	with
O	113	122	oestrogen
O	123	131	receptor
O	131	132	-
O	132	140	positive
O	141	144	and
O	145	149	HER2
O	149	150	-
O	150	158	negative
O	158	159	,
O	160	165	lymph
O	166	170	node
O	170	171	-
O	171	179	positive
O	180	186	breast
O	187	193	cancer
O	193	194	.

O	195	206	Neoadjuvant
O	207	216	endocrine
O	217	224	therapy
O	225	226	(
O	226	229	NET
O	229	230	)
O	231	234	has
O	235	247	demonstrated
O	248	256	efficacy
O	257	259	in
O	260	264	post
O	264	265	-
O	265	275	menopausal
O	276	284	patients
O	285	289	with
O	290	297	hormone
O	297	298	-
O	298	308	responsive
O	309	315	breast
O	316	322	cancer
O	322	323	.

O	324	328	This
O	329	334	trial
O	335	338	was
O	339	347	designed
O	348	350	to
O	351	358	compare
O	359	362	the
O	363	371	efficacy
O	372	374	of
O	375	386	neoadjuvant
O	387	399	chemotherapy
O	400	401	(
O	401	404	NCT
O	404	405	)
O	406	410	with
O	411	414	NET
O	415	417	in
O	418	421	pre
O	421	422	-
O	422	432	menopausal
O	433	439	breast
O	440	446	cancer
O	446	447	.

O	448	450	In
O	451	455	this
O	456	467	prospective
O	467	468	,
O	469	479	randomised
O	479	480	,
O	481	486	phase
O	487	490	III
O	491	496	study
O	496	497	,
O	498	507	oestrogen
O	508	516	receptor
O	517	518	(
O	518	520	ER
O	520	521	)
O	521	522	-
O	522	530	positive
O	530	531	,
O	532	536	HER2
O	536	537	-
O	537	545	negative
O	545	546	,
O	547	550	and
O	551	556	lymph
O	557	561	node
O	561	562	-
O	562	570	positive
O	571	574	pre
O	574	575	-
O	575	585	menopausal
O	586	592	breast
O	593	599	cancer
O	600	608	patients
O	609	613	were
O	614	623	recruited
O	624	628	from
O	629	630	7
O	631	640	hospitals
O	641	643	in
O	644	649	South
O	650	655	Korea
O	655	656	.

O	657	665	Enrolled
O	666	674	patients
O	675	679	were
O	680	688	randomly
O	689	697	assigned
O	698	699	(
O	699	700	1
O	700	701	:
O	701	702	1
O	702	703	)
O	704	706	to
O	707	714	receive
O	715	717	24
O	718	723	weeks
O	724	726	of
O	727	733	either
O	734	737	NCT
O	738	740	or
O	741	744	NET
O	745	749	with
O	750	759	goserelin
O	760	763	and
O	764	773	tamoxifen
O	773	774	.

O	775	778	The
O	779	786	primary
O	787	794	purpose
O	795	798	was
O	799	801	to
O	802	810	evaluate
O	811	814	the
O	815	818	non
O	818	819	-
O	819	830	inferiority
O	831	833	of
O	834	837	NET
O	838	846	compared
O	847	849	to
O	850	853	NCT
O	854	859	using
B-outcome-Measure	860	868	clinical
I-outcome-Measure	869	877	response
O	877	878	,
O	879	887	assessed
O	888	890	by
O	891	894	MRI
O	894	895	.

O	896	903	Besides
O	903	904	,
O	905	917	pathological
O	918	926	complete
O	927	935	response
O	936	940	rate
O	941	942	(
O	942	945	pCR
O	945	946	)
O	946	947	,
O	948	955	changes
O	956	958	in
O	959	961	Ki
O	961	962	-
O	962	964	67
O	965	975	expression
O	975	976	,
O	977	983	breast
O	984	996	conservation
O	997	1004	surgery
O	1005	1006	(
O	1006	1009	BCS
O	1009	1010	)
O	1011	1015	rate
O	1015	1016	,
O	1017	1020	and
O	1021	1028	quality
O	1029	1031	of
O	1032	1036	life
O	1037	1041	were
O	1042	1050	included
O	1051	1053	as
O	1054	1063	secondary
O	1064	1073	endpoints
O	1073	1074	.

O	1075	1076	A
O	1077	1082	total
O	1083	1085	of
B-total-participants	1086	1089	187
O	1090	1098	patients
O	1099	1103	were
O	1104	1112	assigned
O	1113	1115	to
O	1116	1123	receive
O	1124	1127	NCT
O	1128	1129	(
O	1129	1130	n
O	1131	1132	=
B-control-participants	1133	1135	95
O	1135	1136	)
O	1137	1139	or
O	1140	1143	NET
O	1144	1145	(
O	1145	1146	n
O	1147	1148	=
B-intervention-participants	1149	1151	92
O	1151	1152	)
O	1152	1153	,
O	1154	1157	and
O	1158	1160	87
O	1161	1169	patients
O	1170	1172	in
O	1173	1177	each
O	1178	1183	group
O	1184	1193	completed
O	1194	1204	treatments
O	1204	1205	.

O	1206	1210	More
O	1211	1214	NCT
O	1215	1223	patients
O	1224	1227	had
B-outcome	1228	1236	complete
I-outcome	1237	1245	response
I-outcome	1246	1248	or
I-outcome	1249	1256	partial
I-outcome	1257	1265	response
O	1266	1270	than
O	1271	1274	NET
O	1275	1283	patients
O	1284	1289	using
O	1290	1293	MRI
O	1294	1295	(
O	1295	1298	NCT
B-cv-bin-percent	1299	1301	83
I-cv-bin-percent	1301	1302	.
I-cv-bin-percent	1302	1303	7
I-cv-bin-percent	1303	1304	%
O	1305	1307	vs
O	1307	1308	.
O	1309	1312	NET
B-iv-bin-percent	1313	1315	52
I-iv-bin-percent	1315	1316	.
I-iv-bin-percent	1316	1317	9
I-iv-bin-percent	1317	1318	%
O	1318	1319	,
O	1320	1322	95
O	1322	1323	%
O	1324	1326	CI
O	1327	1329	17
O	1329	1330	.
O	1330	1331	6
O	1331	1332	-
O	1332	1334	44
O	1334	1335	.
O	1335	1336	0
O	1336	1337	,
O	1338	1339	p
O	1340	1341	<
O	1342	1343	0
O	1343	1344	.
O	1344	1347	001
O	1347	1348	)
O	1349	1352	and
B-outcome	1353	1362	callipers
O	1363	1364	(
O	1364	1367	NCT
B-cv-bin-percent	1368	1370	83
I-cv-bin-percent	1370	1371	.
I-cv-bin-percent	1371	1372	9
I-cv-bin-percent	1372	1373	%
O	1374	1376	vs
O	1376	1377	.
O	1378	1381	NET
B-iv-bin-percent	1382	1384	71
I-iv-bin-percent	1384	1385	.
I-iv-bin-percent	1385	1386	3
I-iv-bin-percent	1386	1387	%
O	1387	1388	,
O	1389	1391	95
O	1391	1392	%
O	1393	1395	CI
O	1396	1397	0
O	1397	1398	.
O	1398	1399	4
O	1399	1400	-
O	1400	1402	24
O	1402	1403	.
O	1403	1404	9
O	1404	1405	,
O	1406	1407	p
O	1408	1409	=
O	1410	1411	0
O	1411	1412	.
O	1412	1415	046
O	1415	1416	)
O	1416	1417	.

B-cv-bin-abs	1418	1423	Three
O	1424	1427	NCT
O	1428	1436	patients
O	1437	1438	(
B-cv-bin-percent	1438	1439	3
I-cv-bin-percent	1439	1440	.
I-cv-bin-percent	1440	1441	4
I-cv-bin-percent	1441	1442	%
O	1442	1443	)
O	1444	1447	and
B-iv-bin-abs	1448	1451	one
O	1452	1455	NET
O	1456	1463	patient
O	1464	1465	(
B-iv-bin-percent	1465	1466	1
I-iv-bin-percent	1466	1467	.
I-iv-bin-percent	1467	1468	2
I-iv-bin-percent	1468	1469	%
O	1469	1470	)
O	1471	1477	showed
B-outcome	1478	1481	pCR
O	1482	1483	(
O	1483	1484	p
O	1485	1486	<
O	1487	1488	0
O	1488	1489	.
O	1489	1492	005
O	1492	1493	)
O	1493	1494	.

O	1495	1497	No
O	1498	1508	difference
O	1509	1516	existed
O	1517	1519	in
O	1520	1523	the
B-outcome	1524	1534	conversion
I-outcome	1535	1539	rate
I-outcome	1540	1542	of
I-outcome	1543	1546	BCS
O	1547	1548	(
B-cv-bin-percent	1548	1550	13
I-cv-bin-percent	1550	1551	.
I-cv-bin-percent	1551	1552	8
I-cv-bin-percent	1552	1553	%
O	1554	1557	for
O	1558	1561	NCT
O	1562	1564	vs
O	1564	1565	.
B-iv-bin-percent	1566	1568	11
I-iv-bin-percent	1568	1569	.
I-iv-bin-percent	1569	1570	5
I-iv-bin-percent	1570	1571	%
O	1572	1575	for
O	1576	1579	NET
O	1579	1580	,
O	1581	1582	p
O	1583	1584	=
O	1585	1586	0
O	1586	1587	.
O	1587	1590	531
O	1590	1591	)
O	1592	1595	and
O	1596	1598	Ki
O	1598	1599	-
O	1599	1601	67
O	1602	1608	change
O	1609	1610	(
O	1610	1611	p
O	1612	1613	=
O	1614	1615	0
O	1615	1616	.
O	1616	1619	114
O	1619	1620	)
O	1621	1628	between
O	1629	1632	the
O	1633	1636	two
O	1637	1643	groups
O	1643	1644	.

B-cv-bin-abs	1645	1653	Nineteen
O	1654	1657	NCT
O	1658	1666	patients
O	1667	1670	had
O	1671	1680	treatment
O	1680	1681	-
O	1681	1688	related
B-outcome	1689	1694	grade
I-outcome	1695	1696	3
I-outcome	1697	1699	or
I-outcome	1700	1705	worse
I-outcome	1706	1712	events
O	1713	1721	compared
O	1722	1726	with
B-iv-bin-abs	1727	1731	none
O	1732	1734	in
O	1735	1738	the
O	1739	1742	NET
O	1743	1748	group
O	1748	1749	.

O	1750	1756	Better
B-outcome	1757	1765	clinical
I-outcome	1766	1775	responses
O	1776	1780	were
O	1781	1789	observed
O	1790	1792	in
O	1793	1796	pre
O	1796	1797	-
O	1797	1807	menopausal
O	1808	1816	patients
O	1817	1822	after
O	1823	1825	24
O	1826	1831	weeks
O	1832	1834	of
O	1835	1838	NCT
O	1839	1847	compared
O	1848	1850	to
O	1851	1856	those
O	1857	1865	observed
O	1866	1871	after
O	1872	1875	NET
O	1875	1876	.

O	1877	1891	Clinicaltrials
O	1891	1892	.
O	1893	1896	gov
O	1896	1897	,
O	1898	1909	NCT01622361
O	1909	1910	.

O	1911	1923	Registration
O	1924	1928	June
O	1929	1931	19
O	1931	1932	,
O	1933	1937	2012
O	1937	1938	.
